• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CIDRAP- NIAID: Zika is caused by 1 serotype

Shiloh

Editor, Senior Moderator
Source: http://www.cidrap.umn.edu/news-perspective/2016/08/niaid-zika-caused-1-serotype


NIAID: Zika is caused by 1 serotype
Filed Under:
Zika
Stephanie Soucheray | News Reporter | CIDRAP News
| Aug 03, 2016

A new study published in Cell Reports said Zika virus infection is caused by only one serotype, and vaccinating against that one strain could offer protection from diverse strains of the arbovirus. This promising news comes as human Zika vaccine trials begin.
To determine Zika's serotype, researchers with the National Institute of Allergy and Infectious Diseases (NIAID) investigated serum samples from eight people who'd recently been infected with the virus in South America. They mixed the samples with multiple strains of the virus to see if serum antibodies neutralized the virus.
"Antibodies elicited after infection with Zika virus strains of the Asian lineage were able to potently inhibit both Asian lineage and African lineage strains," the researchers said in an NIAID news release.
[h=3]Study offers focus for vaccine development[/h] "Vaccination against a single strain of Zika virus should be sufficient to protect against genetically diverse strains of the virus," according to the release.
Theodore Pierson, PhD, chief of the viral pathogenesis section of NIAID's laboratory of viral disease and a lead author on the study, said the goal was to determine whether or not strain variation would be important in developing vaccines.
"In certain viruses, like influenza, the strain you use in vaccine development is very important," he said. "But we saw that antibodies elicited by recent infections were capable of neutralizing both strains."
This means a vaccine targeting the virus would produce broadly neutralizing antibodies against all Zika infections, coming from either the African or Asian strain. The current outbreak in Americas is caused by the Asian strain of the virus.
Pierson said that, unlike dengue virus, infection with different strains of Zika isn't likely to cause new or worsening disease, and one vaccine could be protective against various strains of Zika.
"When the body is challenged with a virus, it's possible it could mount different antibodies based on the serotypes it sees," said Pierson. "But that's not what we saw [with Zika]."
See also:
Jul 29 Cell Rep study
Jul 29 NIAID release
 
Back
Top Bottom